Literature DB >> 19454067

Leprosy.

Diana Nj Lockwood1.   

Abstract

INTRODUCTION: The World Health Organization field leprosy classification is based on the number of skin lesions: single-lesion leprosy (1 lesion), paucibacillary leprosy (2-5 skin lesions), and multibacillary leprosy (more than 5 skin lesions). Worldwide, about 720,000 new cases of leprosy are reported each year, and about 2 million people have leprosy-related disabilities. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent leprosy? What are the effects of treatments for leprosy? We searched: Medline, Embase, The Cochrane Library and other important databases up to March 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 20 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: Bacillus Calmette Guerin (BCG) plus killed Mycobacterium leprae vaccine; BCG vaccine; ICRC vaccine; multidrug treatment; multiple-dose treatment; mycobacterium w vaccine; single-dose treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19454067      PMCID: PMC2943824     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  32 in total

1.  Relapses after fixed duration multiple drug therapy: the AMFES cohort.

Authors:  S Gebre; P Saunderson; P Byass
Journal:  Lepr Rev       Date:  2000-09       Impact factor: 0.537

2.  BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea, 1963-79.

Authors:  A Bagshawe; G C Scott; D A Russell; S C Wigley; A Merianos; G Berry
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

3.  Leprosy after starting antiretroviral treatment.

Authors:  Stephen D Lawn; Diana N J Lockwood
Journal:  BMJ       Date:  2007-02-03

4.  A study of relapse in paucibacillary leprosy in a multidrug therapy project, Baroda District, India.

Authors:  N K Chopra; J S Agarawal; P G Pandya
Journal:  Lepr Rev       Date:  1990-06       Impact factor: 0.537

5.  The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome.

Authors:  P Saunderson; S Gebre; K Desta; P Byass; D N Lockwood
Journal:  Lepr Rev       Date:  2000-09       Impact factor: 0.537

Review 6.  Drug resistance in leprosy--a review.

Authors:  B H Ji
Journal:  Lepr Rev       Date:  1985-12       Impact factor: 0.537

7.  WHO Expert Committee on Leprosy.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1988

Review 8.  Chemotherapy of leprosy. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

9.  Relapses in multibacillary leprosy patients: effect of length of therapy.

Authors:  B K Girdhar; A Girdhar; A Kumar
Journal:  Lepr Rev       Date:  2000-06       Impact factor: 0.537

10.  Preliminary appraisal of a WHO-recommended multiple drug regimen in paucibacillary leprosy patients in Malawi.

Authors:  G Boerrigter; J M Ponnighaus; P E Fine
Journal:  Int J Lepr Other Mycobact Dis       Date:  1988-09
View more
  1 in total

1.  Cytokine and Chemokine Concentrations as Biomarkers of Feline Mycobacteriosis.

Authors:  C O'Halloran; L McCulloch; L Rentoul; J Alexander; J C Hope; D A Gunn-Moore
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.